Link between patient preferences and treatment outcomes in seasonal allergic rhinitis: an empiric investigation.
In a multicenter, parallel-group, double-masked, randomized study, two questionnaires were administered to a clinical study population to identify which specific symptoms of seasonal allergic rhinitis patients perceived as most important to relieve (personal preferences) and to learn whether any relationship existed between patient preferences and the severity of their symptoms during treatment with antihistamines. The group was composed of 256 males and 313 females. Their mean age was 32.4 years, and mean duration of seasonal allergic rhinitis was 14.5 years, with mean age of onset of 17.7 years. After receiving placebo for 1 week, patients were randomly allocated to receive an antihistamine (fexofenadine or loratadine) for 2 weeks. Patient preferences for relief of individual allergy symptoms (rhinitis; sneezing; itchy, watery, red eyes; itchy nose, palate, or throat) and related conditions (fatigue, physical limitations) were scored using 2 different questionnaires before treatment (0-to-10 category rating scale for assessing the 4 symptoms of allergic rhinitis) and after receiving placebo for 1 week (Feeling Thermometer). Symptom severity was reported in patient diaries after 1 and 2 weeks of antihistamine treatment and was measured by patient self-assessment. All symptoms were considered by the patients to be important to relieve, the most important being itchy, watery, red eyes and rhinorrhea. The severity of allergy symptoms was consistently related to the importance of symptoms identified before treatment. Therefore, including patient preferences in medical evaluations might be a useful tool in evaluating the success of their treatment.
Ricard
N
N
Health Economics, Hoechst Marion Roussel Canada Inc., Laval, Quebec.
Kind
P
P
Christian
S
S
Jensen
M
M
Stewart
J
J
D000328:Adult; D004311:Double-Blind Method; D005260:Female; D006634:Histamine H1 Antagonists / Q000627:therapeutic use*; D006801:Humans; D017336:Loratadine / Q000627:therapeutic use*; D008297:Male; D017060:Patient Satisfaction; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy*; D011795:Surveys and Questionnaires; D016593:Terfenadine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
D006634:Histamine H1 Antagonists; D017336:Loratadine; D016593:Terfenadine; C093230:fexofenadine